The Division of Cardiology is home to vibrant, externally funded basic, translational, and clinical research programs. The Divisional research portfolio has increased to over $25,000,000 annually, with numerous grants from the National Institutes of Health, American Heart Association, Burroughs-Wellcome Fund, Doris Duke Charitable Foundation, and other agencies and philanthropies.
Much of the basic and translational cardiovascular investigation within the Medical Center is organized under the auspices of the Cardiovascular Research Program, which is located in the Joan and Joel Smilow Translational Research Center. Two floors in this state-of-the-art research facility, totalling 24,000 sq. ft. of space, are devoted to cardiovascular investigation, with vibrant highly translational programs in myocardial biology, cardiovascular development, stem cells, ion channels and arrhythmia mechanisms, computational modeling, thrombosis and vascular biology. Principal investigators in Smilow include: Drs. Glenn I. Fishman, Jeffrey Berger, Mario Delmar, Boyce Griffith, Gregory Morley, Edward A. Fisher, Kathryn Moore, Carlos Fernandez-Hernando and Yajaira Suarez. We invite you to explore their websites for additional information.
Over the past several decades, clinical research activities in the Division of Cardiology have contributed substantially to the cardiovascular literature and have greatly influenced the practice of clinical cardiology. Our Cardiovascular Clinical Research Center (CCRC) is directed by Dr. Judith Hochman. Considered one of the world’s leading cardiovascular clinical trialists, Dr. Hochman and her team were recently awarded an $84 million grant from the NIH for the ISCHEMIA trial, an 8 year randomized-controlled comparative effectiveness study of patients with significant coronary artery disease. This is the largest NIH grant ever received at NYU Langone Medical Center. Our Cardiac Electrophysiology team, directed by Dr. Larry Chinitz, oversees a substantial clinical research program focused on the development of electroanatomic mapping systems and tools required for catheter ablation of atrial arrhythmias. His team, working closely with industry partners, is also examining spinal cord stimulation as a novel anti-arrhythmic strategy. Dr. Silvia Priori, Director of our Cardiovascular Genetics Program, is exploring novel translational therapies for patients at risk of inherited forms of arrhythmic diseases, in close collaboration with our Cadiac Electrophysiology faculty. Dr. Stuart D. Katz, Director of the NYU-Langone Heart Failure Program and a nationally prominent NIH-funded clinical investigator, is exploring the importance of vascular dysregulation in heart failure as well as the cytoprotective role of erythropoietin in acute coronary syndromes. James Slater, Director of our Cardiac Catheterization Laboratory, is involved new strategies to treat structural heart disease, including EVEREST and CoreValve.